21.05.2024 13:31:30

Halozyme: Bristol Myers Gets New PDUFA Date For Subcutaneous Nivolumab Co-Formulated With ENHANZE

(RTTNews) - Halozyme Therapeutics, Inc. (HALO) said Bristol Myers Squibb was reassigned a Prescription Drug User Fee Act goal date from the FDA for their Biologics License Application for the subcutaneous formulation of Opdivo co-formulated with ENHANZE, Halozyme's recombinant human hyaluronidase enzyme, rHuPH20, across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. The updated goal date is December 29, 2024.

The application is based on results from CheckMate-67T, the first Phase 3 trial of the subcutaneous formulation of nivolumab with ENHANZE.

For More Such Health News, visit rttnews.com.

Analysen zu Halozyme Therapeutics Inc.mehr Analysen

15.11.24 Halozyme Therapeutics Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Halozyme Therapeutics Inc. 45,80 0,00% Halozyme Therapeutics Inc.